Neutralizing antibodies against KP.2 and KP.3: why the current vaccine needs an update

Clin Chem Lab Med. 2024 Aug 16. doi: 10.1515/cclm-2024-0919. Online ahead of print.

Constant Gillot¹, Clara David², Jean-Michel Dogné¹, Julien Cabo³, Jonathan Douxfils^{1

2

4}, Julien Favresse^{1

3}

¹ Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium.
² Research and Development Department, Qualiblood s.a., Namur, Belgium.
³ Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium.
⁴ Department of Biological Hematology, Centre Hospitalier Universitaire Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand, France.

No abstract available

Keywords: KP.2; KP.3; SARS-CoV-2; humoral response; vaccination.

Publication types